Product Description: Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Magee K, et al. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. PLoS One. 2021 Aug 12;16(8):e0255798.